Glenmark Pharmaceuticals (NSE:GLENMARK) E10: ₹30.21 (As of Mar. 2026)


NSE:GLENMARK Glenmark Pharmaceuticals Ltd NSE:GLENMARK
88 GF Score
Price ₹2,211.00
GF Value ₹1,988.21
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Glenmark Pharmaceuticals E10?

Glenmark Pharmaceuticals NSE:GLENMARK +0.68% 88 E10 is ₹30.21 as of Mar. 2026. GuruFocus rates NSE:GLENMARK with a GF Score™ of 88/100 and a GF Value™ of ₹1,988.21 (Modestly Overvalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Glenmark Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2026 was ₹10.680. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is ₹30.21 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Glenmark Pharmaceuticals's average E10 Growth Rate was 6.30% per year. During the past 3 years, the average E10 Growth Rate was -3.90% per year. During the past 5 years, the average E10 Growth Rate was -3.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Glenmark Pharmaceuticals was 3.30% per year. The lowest was -6.70% per year. And the median was -5.25% per year.

As of today (2026-07-05), Glenmark Pharmaceuticals's current stock price is ₹2211.00. Glenmark Pharmaceuticals's E10 for the quarter that ended in Mar. 2026 was ₹30.21. Glenmark Pharmaceuticals's Shiller PE Ratio of today is 73.19.

During the past 13 years, the highest Shiller PE Ratio of Glenmark Pharmaceuticals was 79.65. The lowest was 6.37. And the median was 17.97.


Glenmark Pharmaceuticals  (NSE:GLENMARK) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Glenmark Pharmaceuticals's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=2211.00/30.21
=73.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Glenmark Pharmaceuticals was 79.65. The lowest was 6.37. And the median was 17.97.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Glenmark Pharmaceuticals E10 Related Terms


Glenmark Pharmaceuticals E10 Historical Data

* Premium members only.

The historical data trend for Glenmark Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Glenmark Pharmaceuticals E10 Chart

Glenmark Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 34.98 34.07 26.85 28.47 30.21

Glenmark Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.47 27.92 29.29 29.78 30.21

NSE:GLENMARK vs ZTS, UTHR: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Glenmark Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glenmark Pharmaceuticals Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Glenmark Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Glenmark Pharmaceuticals's Shiller PE Ratio falls into.


NSE:GLENMARK
88GF Score
Glenmark Pharmaceuticals Ltd NSE:GLENMARK
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Glenmark Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Glenmark Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=10.68/164.2724*164.2724
=10.680

Current CPI (Mar. 2026) = 164.2724.

Glenmark Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201606 7.730 105.961 11.984
201609 7.770 105.961 12.046
201612 16.290 105.196 25.438
201703 0.750 105.196 1.171
201706 11.810 107.109 18.113
201709 7.240 109.021 10.909
201712 3.310 109.404 4.970
201803 5.350 109.786 8.005
201806 8.260 111.317 12.189
201809 14.670 115.142 20.930
201812 4.120 115.142 5.878
201903 5.730 118.202 7.963
201906 3.870 120.880 5.259
201909 9.060 123.175 12.083
201912 6.760 126.235 8.797
202003 7.810 124.705 10.288
202006 9.000 127.000 11.641
202009 8.290 130.118 10.466
202012 8.800 130.889 11.044
202103 8.290 131.771 10.335
202106 10.860 134.084 13.305
202109 9.130 135.847 11.040
202112 7.860 138.161 9.346
202203 5.510 138.822 6.520
202206 6.820 142.347 7.870
202209 9.230 144.661 10.481
202212 9.660 145.763 10.887
202303 -15.180 146.865 -16.979
202306 5.310 150.280 5.804
202309 -2.900 151.492 -3.145
202312 -12.450 152.924 -13.374
202403 -43.180 153.035 -46.351
202406 12.060 155.789 12.717
202409 12.550 157.882 13.058
202412 12.330 158.323 12.793
202503 0.160 157.552 0.167
202506 1.660 159.755 1.707
202509 21.620 162.289 21.884
202512 14.280 163.281 14.367
202603 10.680 164.272 10.680

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of ₹30.21 mean?
Glenmark Pharmaceuticals (NSE:GLENMARK) has a E10 of ₹30.21 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Glenmark Pharmaceuticals and its competitors.
Is Glenmark Pharmaceuticals' E10 too high?
Glenmark Pharmaceuticals' current E10 is ₹30.21. Overall, Glenmark Pharmaceuticals has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Glenmark Pharmaceuticals' E10 compare to ZTS and UTHR?
Glenmark Pharmaceuticals' E10 of ₹30.21 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Glenmark Pharmaceuticals and its competitors. Glenmark Pharmaceuticals's current E10 is ₹30.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glenmark Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Glenmark Pharmaceuticals (NSE:GLENMARK) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,988.21, compared to a current price of ₹2,211.00 — trading 11.2% above its estimated fair value. The current E10 is ₹30.21. Glenmark Pharmaceuticals' overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Glenmark Pharmaceuticals (NSE:GLENMARK), the current E10 is ₹30.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Glenmark Pharmaceuticals (NSE:GLENMARK) Overvalued in 2026?

Based on GuruFocus' analysis, Glenmark Pharmaceuticals stock appears to be overvalued. The current stock price of ₹2,211.00 is trading 11.2% above its estimated GF Value™ of ₹1,988.21. GuruFocus considers Glenmark Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for NSE:GLENMARK:

  • E10: ₹30.21
  • GF Value™: ₹1,988.21 vs. price of ₹2,211.00 (11.2% above fair value)
  • GF Score™: 88/100 with 2 warning signs

No single metric tells the full story. See the NSE:GLENMARK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Glenmark Pharmaceuticals Business Description

Other Exchanges 532296:India
Address B. D. Sawant Marg, Glenmark House, Chakala, Off Western Express Highway, Andheri (East), Mumbai, MH, IND, 400099
Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities. It has a business presence in different therapeutic areas such as dermatology, respiratory, oncology, diabetes, cardiovascular, and oral contraceptives among others. Geographically, it derives key revenue from India and the rest from North America, Latin America, Europe and the Rest of the world.
88GF Score

Get the complete analysis for NSE:GLENMARK

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,211.00
Price
₹1,988.21
GF Value